GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, ...

Tigilanol tiglate is under clinical development by QBiotics Group and currently in Phase I for Adenocarcinoma.

Your vulva might also be itchy. Pain, bleeding, and ulcers are later-stage symptoms. Vulvar basal cell carcinoma (BCC) is a type of skin cancer that develops when basal cells (cells that shed as ...

A new study published recently in the journal Gut shows children with Crohn's who were prescribed anti-TNF (tumor necrosis ...

Getty Images Understanding current trends in the incidence, prevalence, and distribution of ulcerative colitis can help inform diagnosis and treatment. Most incidence and prevalence studies for UC ...

The Election Commission has terminated its contract with Bangladesh Computer Council (BCC) for National Identification (NID) data verification services due to a breach of terms. ASM Humayun Kabir ...

Add articles to your saved list and come back to them any time. A flesh-eating ulcer has taken root in a NSW holiday hotspot and poses a significant risk of spreading to Sydney. Batemans Bay on ...

Stomach ulcers occur when digestive acids damage your stomach lining. Treatment may include antibiotics, home remedies, or surgery, depending on the underlying cause. Stomach ulcers, also known as ...

If you have an ulcer, you need to be very careful with over-the-counter pain medicines. Remember: No drug is risk-free. It is very important to discuss the use of over-the-counter drugs with your ...

The lesion began as a small birthmark and has continued to grow, and is now ulcerated. The lesion is painful and has begun to ooze. The lesion is a large erythematous plaque with ulceration ...

Several components of the hedgehog (Hh) pathway are crucial to basal cell carcinoma (BCC) tumorigenesis. Primary cilia have emerged as key organelles in Hh signal transduction in mammalian systems ...

The FDA has approved cosibelimab, a new drug for adults with advanced cutaneous squamous cell carcinoma (CSCC), a type of skin cancer. It is the first and only PD-L1 blocker approved to treat ...